HLB Co., Ltd. (028300.KQ)
KRW 70500.0
(-1.26%)
KRW 70500.0
(-1.26%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -1559.61 KRW | -124.66% |
| 2022 | -694.20 KRW | 14.98% |
| 2021 | -816.50 KRW | -26.08% |
| 2020 | -647.59 KRW | -47.77% |
| 2019 | -438.25 KRW | -265.17% |
| 2018 | 265.34 KRW | 246.72% |
| 2017 | -180.85 KRW | -23.93% |
| 2016 | -145.93 KRW | -197.02% |
| 2015 | 150.41 KRW | 734.37% |
| 2014 | -23.71 KRW | 79.66% |
| 2013 | -116.58 KRW | -6.83% |
| 2012 | -109.13 KRW | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | -790.74 KRW | -421.56% |
| 2024 Q1 | 247.23 KRW | 127.01% |
| 2023 Q4 | -915.42 KRW | -458.18% |
| 2023 Q2 | -228.57 KRW | -41.18% |
| 2023 Q1 | -161.90 KRW | 50.07% |
| 2023 Q3 | -164.00 KRW | 28.25% |
| 2023 FY | - KRW | -124.66% |
| 2022 Q3 | -264.53 KRW | -607.54% |
| 2022 Q4 | -324.24 KRW | -22.57% |
| 2022 Q2 | 52.12 KRW | 139.84% |
| 2022 Q1 | -130.83 KRW | 72.68% |
| 2022 FY | - KRW | 14.98% |
| 2021 Q2 | -266.01 KRW | -73.3% |
| 2021 Q4 | -478.89 KRW | -682.73% |
| 2021 Q3 | 82.18 KRW | 130.89% |
| 2021 FY | - KRW | -26.08% |
| 2021 Q1 | -153.50 KRW | 18.85% |
| 2020 Q4 | -189.16 KRW | -651.97% |
| 2020 FY | - KRW | -47.77% |
| 2020 Q2 | -416.14 KRW | -226.95% |
| 2020 Q1 | -127.28 KRW | -189.24% |
| 2020 Q3 | 34.27 KRW | 108.24% |
| 2019 Q2 | -749.63 KRW | -589.0% |
| 2019 FY | - KRW | -265.17% |
| 2019 Q4 | 142.63 KRW | -34.06% |
| 2019 Q3 | 216.29 KRW | 128.85% |
| 2019 Q1 | -108.80 KRW | -168.67% |
| 2018 Q4 | 158.43 KRW | 293.37% |
| 2018 FY | - KRW | 246.72% |
| 2018 Q2 | -90.49 KRW | -131.48% |
| 2018 Q1 | 287.49 KRW | 574.8% |
| 2018 Q3 | -81.93 KRW | 9.46% |
| 2017 Q1 | -24.09 KRW | 74.67% |
| 2017 FY | - KRW | -23.93% |
| 2017 Q4 | -60.55 KRW | 14.69% |
| 2017 Q3 | -70.98 KRW | -96.24% |
| 2017 Q2 | -36.17 KRW | -50.15% |
| 2016 FY | - KRW | -197.02% |
| 2016 Q4 | -95.12 KRW | -232.12% |
| 2016 Q3 | -28.64 KRW | -26.0% |
| 2016 Q2 | -22.73 KRW | -168.36% |
| 2016 Q1 | -8.47 KRW | -104.6% |
| 2015 Q1 | -11.11 KRW | -43.73% |
| 2015 Q4 | 184.07 KRW | 1064.22% |
| 2015 Q3 | -19.09 KRW | 39.63% |
| 2015 Q2 | -31.62 KRW | -184.61% |
| 2015 FY | - KRW | 734.37% |
| 2014 Q2 | -22.55 KRW | -516.82% |
| 2014 Q4 | -7.73 KRW | -562.87% |
| 2014 Q1 | 5.41 KRW | 107.64% |
| 2014 FY | - KRW | 79.66% |
| 2014 Q3 | 1.67 KRW | 107.41% |
| 2013 Q1 | -25.62 KRW | 10.51% |
| 2013 Q3 | 9.96 KRW | 133.9% |
| 2013 FY | - KRW | -6.83% |
| 2013 Q4 | -70.84 KRW | -811.24% |
| 2013 Q2 | -29.38 KRW | -14.68% |
| 2012 Q4 | -28.63 KRW | 54.61% |
| 2012 FY | - KRW | 0.0% |
| 2012 Q3 | -63.08 KRW | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| iNtRON Biotechnology, Inc. | -292.11 KRW | -433.912% |
| BINEX Co., Ltd. | 151.04 KRW | 1132.581% |
| Bioneer Corporation | -410.19 KRW | -280.216% |
| Anterogen.Co.,Ltd. | -291.93 KRW | -434.241% |
| MEDIPOST Co., Ltd. | 287.00 KRW | 643.418% |
| CrystalGenomics, Inc. | -661.00 KRW | -135.947% |
| Helixmith Co., Ltd | -1543.76 KRW | -1.027% |
| Chabiotech Co.,Ltd. | -149.80 KRW | -941.128% |
| Medy-Tox Inc. | 1456.65 KRW | 207.068% |
| Peptron, Inc. | -773.61 KRW | -101.602% |
| Amicogen, Inc. | -583.58 KRW | -167.249% |
| Genexine, Inc. | -1652.14 KRW | 5.601% |
| HLB Therapeutics Co.,Ltd. | -32.12 KRW | -4755.573% |
| LegoChem Biosciences, Inc. | -2595.00 KRW | 39.899% |
| ALTEOGEN Inc. | -65.27 KRW | -2289.474% |
| PharmaResearch Co., Ltd. | 7502.00 KRW | 120.789% |
| SillaJen, Inc. | -179.98 KRW | -766.546% |
| JETEMA, Co., Ltd. | 783.21 KRW | 299.131% |
| OliX Pharmaceuticals,Inc | -1323.81 KRW | -17.812% |
| Genomictree Inc. | -391.00 KRW | -298.877% |
| MedPacto, Inc. | -1664.87 KRW | 6.322% |
| D&D Pharmatech | 409.19 KRW | 481.146% |
| EASY BIO,Inc. | 455.00 KRW | 442.771% |
| GI Innovation, Inc. | -1285.69 KRW | -21.305% |